These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 16209089)
21. The "in vitro" activity of rifampicin compared with ethambutol, capreomycin and isoniazid. Steinbrück PW Acta Tuberc Pneumol Belg; 1969; 60(3):413-6. PubMed ID: 4984421 [No Abstract] [Full Text] [Related]
22. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. Piddock LJ; Williams KJ; Ricci V J Antimicrob Chemother; 2000 Feb; 45(2):159-65. PubMed ID: 10660497 [TBL] [Abstract][Full Text] [Related]
23. Characterization of 7-amino-4-methylcoumarin as an effective antitubercular agent: structure-activity relationships. Tandon R; Ponnan P; Aggarwal N; Pathak R; Baghel AS; Gupta G; Arya A; Nath M; Parmar VS; Raj HG; Prasad AK; Bose M J Antimicrob Chemother; 2011 Nov; 66(11):2543-55. PubMed ID: 21917615 [TBL] [Abstract][Full Text] [Related]
24. [Interactions of antitubercular drugs. II. Combined effects of rifampin, ethambutol, capreomycin, viomycin, ethionamide and cycloserine on mycobacterial growth in vitro]. Janowiec M; Zwolska-Kwiek Z Pneumonol Pol; 1983 Dec; 51(12):607-12. PubMed ID: 6199778 [No Abstract] [Full Text] [Related]
25. Genetic characterisation of the ethambutol resistance-determining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations. Perdigão J; Macedo R; Ribeiro A; Brum L; Portugal I Int J Antimicrob Agents; 2009 Apr; 33(4):334-8. PubMed ID: 19097862 [TBL] [Abstract][Full Text] [Related]
26. Effect of inhibitors of cell envelope synthesis on beta-sitosterol side chain degradation by Mycobacterium sp. NRRL MB 3683. Sedlaczek L; Górmiński BM; Lisowska K J Basic Microbiol; 1994; 34(6):387-99. PubMed ID: 7815307 [TBL] [Abstract][Full Text] [Related]
27. [Quality control of culture media for mycobacterium drug sensitivity tests]. Kekkaku; 2003 Aug; 78(8):563-8. PubMed ID: 14582504 [No Abstract] [Full Text] [Related]
28. Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads. West NP; Cergol KM; Xue M; Randall EJ; Britton WJ; Payne RJ Chem Commun (Camb); 2011 May; 47(18):5166-8. PubMed ID: 21384024 [TBL] [Abstract][Full Text] [Related]
29. Ethambutol-sugar hybrids as potential inhibitors of mycobacterial cell-wall biosynthesis. Reynolds RC; Bansal N; Rose J; Friedrich J; Suling WJ; Maddry JA Carbohydr Res; 1999 Apr; 317(1-4):164-79. PubMed ID: 10466213 [TBL] [Abstract][Full Text] [Related]
30. [Drug sensitivity of atypical Mycobacteria isolated from patients to antitubercular agents of the first and second order]. Makarevich NM; Rudoĭ NM Antibiotiki; 1971 Feb; 16(2):149-52. PubMed ID: 4326726 [No Abstract] [Full Text] [Related]
31. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Laszlo A; Rahman M; Espinal M; Raviglione M; Int J Tuberc Lung Dis; 2002 Sep; 6(9):748-56. PubMed ID: 12234129 [TBL] [Abstract][Full Text] [Related]
32. AFM resolves effects of ethambutol on nanomechanics and nanostructures of single dividing mycobacteria in real-time. Wu Y; Sims RC; Zhou A Phys Chem Chem Phys; 2014 Sep; 16(36):19156-64. PubMed ID: 24965038 [TBL] [Abstract][Full Text] [Related]
33. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938 [TBL] [Abstract][Full Text] [Related]
34. [Antitubercular effect of ethambutol in vitro]. Janowiec M Gruzlica; 1969 Jul; 37(7):637-44. PubMed ID: 4981784 [No Abstract] [Full Text] [Related]
35. Synthesis and antitubercular activity of 7-chloro-4-quinolinylhydrazones derivatives. Candéa AL; Ferreira Mde L; Pais KC; Cardoso LN; Kaiser CR; Henriques Md; Lourenço MC; Bezerra FA; de Souza MV Bioorg Med Chem Lett; 2009 Nov; 19(22):6272-4. PubMed ID: 19819134 [TBL] [Abstract][Full Text] [Related]
36. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674 [TBL] [Abstract][Full Text] [Related]
37. [Sensitivity tests of mycobacteria to INH, SM, EMB and RMP in a semi-liquid serum-sauton-agar (author's transl)]. Neubert R Z Erkr Atmungsorgane; 1976; 144(1):63-8. PubMed ID: 823718 [TBL] [Abstract][Full Text] [Related]
38. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China. Shi R; Zhang J; Otomo K; Zhang G; Sugawara I Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128 [TBL] [Abstract][Full Text] [Related]
39. Bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide on Mycobacterium tuberculosis in vitro. Paramasivan CN; Herbert D; Prabhakar R Indian J Med Res; 1993 Jul; 97():145-50. PubMed ID: 8406638 [TBL] [Abstract][Full Text] [Related]